A Randomized, Open-label, Multicenter, Phase III Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma
ID Number 12-0318Principal Investigator(s)
Robert G. Maki
Department(s) or Division(s)
Hematology and Oncology
The purpose of this study is to compare the safety and usefulness of eribulin or dacarbazine on your sarcoma. “Safety” means the side effects you have on the study. “Usefulness” means how your tumor responds to treatment, and how you do in the long term. In this study, we will treat you with either eribulin or dacarbazine, but not both.
The study will also include research testing of sarcoma tumor samples (from tissue taken from a previous surgery or biopsy) and blood samples (collected before and after the first dose of treatment) for the presence of “biomarkers” and what they mean. A biomarker is an objective measure that is used to assess health or make a diagnosis of disease. You will also be asked to complete a quality of life questionnaire about how you are feeling as well.
You may qualify to take part in this research study because you have an advanced sarcoma that is no longer responding to at least 2 standard treatments for sarcoma.
Recruiting Patients: Yes